Arizona State Retirement System Invests $209,000 in Inhibrx, Inc. (NASDAQ:INBX)

Arizona State Retirement System bought a new position in Inhibrx, Inc. (NASDAQ:INBX) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 5,494 shares of the company’s stock, valued at approximately $209,000.

Several other large investors have also recently made changes to their positions in INBX. Swiss National Bank increased its holdings in shares of Inhibrx by 5.6% in the first quarter. Swiss National Bank now owns 22,500 shares of the company’s stock worth $501,000 after purchasing an additional 1,200 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Inhibrx by 1.2% in the first quarter. Bank of New York Mellon Corp now owns 86,174 shares of the company’s stock worth $1,920,000 after purchasing an additional 1,017 shares during the last quarter. HighTower Advisors LLC bought a new stake in Inhibrx during the first quarter worth approximately $223,000. MetLife Investment Management LLC increased its stake in Inhibrx by 49.5% during the first quarter. MetLife Investment Management LLC now owns 17,227 shares of the company’s stock worth $384,000 after acquiring an additional 5,704 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in Inhibrx by 13.1% during the first quarter. Rhumbline Advisers now owns 28,409 shares of the company’s stock worth $633,000 after acquiring an additional 3,299 shares during the last quarter. 82.46% of the stock is owned by institutional investors.

Inhibrx Trading Down 0.4 %

Shares of NASDAQ INBX opened at $34.32 on Monday. The stock has a market capitalization of $1.63 billion, a P/E ratio of -6.82 and a beta of 2.91. The business’s 50 day moving average is $35.86 and its two-hundred day moving average is $29.86. Inhibrx, Inc. has a 1-year low of $14.31 and a 1-year high of $39.79. The company has a debt-to-equity ratio of 4.78, a current ratio of 5.24 and a quick ratio of 5.25.

Inhibrx (NASDAQ:INBX) last released its earnings results on Wednesday, February 28th. The company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.66). The business had revenue of $1.63 million for the quarter, compared to the consensus estimate of $0.10 million. Inhibrx had a negative net margin of 13,408.95% and a negative return on equity of 590.78%. As a group, research analysts expect that Inhibrx, Inc. will post -4.34 EPS for the current year.

Wall Street Analyst Weigh In

INBX has been the topic of several analyst reports. JMP Securities reissued a “market perform” rating on shares of Inhibrx in a research note on Tuesday, January 23rd. Lifesci Capital cut Inhibrx from an “outperform” rating to a “market perform” rating in a research note on Tuesday, January 23rd.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.